Hello PDF

Presentamos el caso de una paciente de 44 años estudiada por amenorrea e hiperprolactinemia. No refería galactorrea, cefalea ni alteraciones en la visión. HIPERPROLACTINEMIA Y PROLACTINOMA. MP Diagnóstico específico: PRL se deben medir en todo paciente con hipogonadismo o. A hiperprolactinemia causa hipogonadismo hipogonadotrófico principalmente por inibir a secreção pulsátil do GnRH, além de inibir diretamente a.

Author: Mikajin Grozahn
Country: India
Language: English (Spanish)
Genre: Technology
Published (Last): 21 June 2011
Pages: 218
PDF File Size: 9.46 Mb
ePub File Size: 14.46 Mb
ISBN: 407-5-11130-177-4
Downloads: 64155
Price: Free* [*Free Regsitration Required]
Uploader: Nikobar

Cancer risk in hyperprolactinemia patients: Cabergoline is a long-acting dopamine receptor agonist which might hiperprolacinemia advantages over bromocriptine. A paciente deve ser monitorada clinicamente a cada trimestre.

The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay.

Hyperprolactinemia is a frequent neuroendocrinological condition that should be approached in an orderly and integral fashion, starting with a complete clinical history. J Yiperprolactinemia Endocrinol Metab. Ben-Jonathan N, Hnasko R.


N Engl J Med. Sobre los desenlaces incluidos en este resumen. As for pregnancy, the drug of choice to induce ovulation still is bromocriptine. Nos macroprolactinomas, o manejo deve ser amehorrea.

There was a problem providing the content you requested

N Engl J Med. In the cases of microprolactinomas and intrasselar macroprolactinomas, the treatment with dopaminergic agonists may be suspended after pregnancy is confirmed. It is not clear whether cabergoline is also more effective with respect to tumor growth because the certainty of the evidence is very low.


Prolactin; hyperprolactinemia; prolactinoma; pseudoprolactinoma; pituitary adenoma; neurosurgery; macroprolactina; dopamine agonist.

Macroprolactinomas may cause cephalea, visual disturbance, and hypopituitarism. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. Cabergolina versus bromocriptina para la hiperprolactinemia o prolactinoma.

Spontaneous and medically induced cerebrospinal fluidleakage in the setting of pituitary adenomas: De los estudios no aleatorizados incluidos, los tres corresponden a cohortes retrospectivas. Prolactinomas in children and adolescents. Su principal desarrollo es la base de datos Epistemonikos www. Management of pituitary tumors in pregnancy.

Primary medical therapy of micro- and macroprolactinomas in men. Clinical treatment with dopamine agonists is the gold standard, with cabergoline as the first choice due to its greater efficiency and tolerability. Once physiological causes such as pregnancy, systemic disorders such as primary hypothyroidism and the use of drugs with dopamine antagonistic actions such as metochlopramide have been ruled out, the most common cause of hyperprolactinemia is a PRL-secreting pituitary adenoma or prolactinoma.

Todos los estudios compararon bromocriptina versus cabergolina. Trans Am Clin Climatol Assoc.

Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. The prevalence of pituitary adenomas: Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Temozolomide in the management of dopamine agonist-resistant po. Quality of life in women with microprolactinoma treated with dopamine agonists.


Aust N Z J Ophthalmol. Prolactinomas are the most common pituitary adenomas that affect young women at fertile age. Prolactin and human tumourogenesis. J Clin Endocrinol Metab.

[Current diagnosis and treatment of hyperprolactinemia].

Comparative effects of bromocriptine and cabergoline on serum prolactin levels, liver and kidney function tests in hyperprolactinemic women. Recentemente, Mazziotti e cols. A study of patients with histologically verified non-functioning pituitary macroadenoma.

Body fat in amejorrea with prolactinoma. Diagnosis and treatment of hyperprolactinemia: Patterns of visual loss associated with pituitary macroadenomas. In macroprolactinomas, management should be individualized.

[Current diagnosis and treatment of hyperprolactinemia].

Advances in the treatment of prolactinomas. Other structural causes of hyperprolactinemia include non-functioning pituitary adenomas and infiltrative disorders, which can interrupt the inhibitory, descending dopaminergic tone. Pituitary tumors in pregnancy.

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea.